

An unusual succinate dehydrogenase gene mutation C in a case of laryngeal paraganglioma

R GARREL, P RAYNAUD*, I RAINGEARD†, C MUYSHONDT, Q GARDINER‡, B GUERRIER, P PUJOL, I COUPIER**§

Abstract

Objective: To report a rare case of a laryngeal paraganglioma related to succinate dehydrogenase gene mutation C.

Method: A case report and a review of the world literature concerning succinate dehydrogenase mutations and laryngeal paraganglioma are presented.

Results: We identified a laryngeal paraganglioma in a 38-year-old woman, related to a very rare, deleterious in exon 4 of the succinate dehydrogenase mutation C. This mutation was a non-sense mutation: c.183G > A leading to p.Trp61X. No other neuroendocrine tumour was identified in this case, but a thyroid papillary carcinoma was concomitantly discovered and cured.

Conclusion: To our knowledge, this is the first report in the world literature of laryngeal paraganglioma related to a succinate dehydrogenase mutation C. The case presented underlines the fact that every patient with paraganglioma should be tested for succinate dehydrogenase genetic mutations, even if a family history of paraganglioma is absent, in order to enable appropriate clinical management and to improve our knowledge of familial paraganglioma.

Key words: Paraganglioma; Laryngeal Neoplasms; SDHC Protein; Human; Germ Line Mutation

Introduction

Paragangliomas are uncommon neuroendocrine tumours arising from neural crest tissue found in various locations around the body.¹ Sympathetic-associated paragangliomas arise from the adrenal medulla or from the sympathetic ganglia and are generally functionally active, as indicated by excess catecholamine production. Parasympathetic-associated paragangliomas arising in the head and neck are usually non-functioning. In the head and neck, paraganglioma of the larynx is rare,^{1,2} with only 79 reported cases in the English language literature.³ Recently, paraganglioma syndromes have been described which are related to succinate dehydrogenase gene mutations.⁴ We report a case of a laryngeal paraganglioma and discuss its genetic origin.

Case report

A 38-year-old woman was referred with a laryngeal mass discovered incidentally during ultrasonography for a solitary thyroid nodule. The patient had no children and no related significant personal or familial medical history. She was asymptomatic, with neither dysphonia nor dyspnoea.

Fibre-optic laryngoscopy revealed a swelling in the area of the left laryngeal ventricle. Computed tomography and magnetic resonance imaging of the area showed a hyper-vascular laryngeal mass with the typical appearance of a paraganglioma, located in the left pre-epiglottic space (Figure 1). The plasma calcitonin level was normal

(<10 µmol/ml), excluding a medullary thyroid carcinoma.⁵ Surgical removal of the paraganglioma was planned, and fine needle aspiration biopsy of the thyroid gland nodule was decided against as the nodule was to be excised during the same procedure.

A neck incision at the level of the thyroid cartilage revealed an extremely vascular mass arising from the left superior laryngeal nerve and involving the lateral part of the pre-epiglottic space (Figure 2), with a blood supply derived from the superior laryngeal artery. The entire excision was performed without breaching the laryngeal mucosa. The thyroid cartilage was not removed. The frozen section histopathological appearance was consistent with a paraganglioma; this was confirmed from formal-fixed, paraffin-embedded sections and immunostaining (Figure 3), excluding, notably, neuroendocrine carcinoma. Paraffin-embedded sections of the thyroid nodule revealed a papillary carcinoma.

A post-operative octreoscan did not show any other paraganglioma. Plasma-free metanephrine analysis was negative, indicating no concomitant secreting pheochromocytoma.

A total thyroidectomy and right modified neck dissection were performed two months later. There were no post-operative complications. Formal histopathological analysis showed a 15 mm papillary carcinoma in the right thyroid lobe associated with a 2 mm microcarcinoma in the contralateral lobe. Subsequently, the patient went on to receive radioiodine treatment.

From the Departments of Otolaryngology, Head and Neck Surgery, *Pathology, †Endocrinology and **Genetics, Montpellier Teaching Hospitals, France, §Val d'Aurelle Hospital, France, and the ‡Department of Otolaryngology, Ninewells Hospital and Medical School, Dundee, Scotland, UK.

Accepted for publication: 7 November 2007. First published online 11 February 2008.



FIG. 1

Axial imaging views taken at the supraglottic level. (a) Iodine-enhanced computed tomography scan; (b) T2-weighted magnetic resonance imaging scan (note 'salt and pepper' appearance).

The coding exons of the succinate dehydrogenase gene B, C and D, including their intron–exon junctions, were analysed by denaturing high performance liquid chromatography. Total human genomic deoxyribonucleic acid (DNA) was obtained from peripheral blood lymphocytes. Genomic DNA was extracted by standard methods. Amplicons with abnormal enhanced mismatch mutation analysis denaturing high performance liquid chromatography profiles were sequenced on both strands (primer sequences are available on request). No deleterious mutation was found in the succinate dehydrogenase B and succinate dehydrogenase D genes. A deleterious in exon 4 of succinate dehydrogenase mutation C was identified. This mutation was a non-sense mutation: c.183G>A leading to p.Trp61X.

Discussion

Although paragangliomas have been described since the late 1940s,^{1,6} their genetic basis has only started to




FIG. 2

Surgical extra-mucosal removal of the laryngeal paraganglioma (P). The superior laryngeal nerve is indicated. L = left thyroid ala of the larynx

become clearer within the last few years.⁴ Hereditary paragangliomas are caused by germline mutation in the genes coding for the mitochondrial complex II, which is part of an enzyme complex found in the mitochondrial protein membrane involved in the Krebs cycle and the mitochondrial respiratory chain. This complex is composed of four sub-units, components of succinate dehydrogenase A, B, C and D. Germline succinate dehydrogenase mutations B, C and D give rise to paraganglioma syndromes four, three and one, respectively. The method of transmission of paraganglioma syndromes four, three and two is autosomal dominant, with maternal imprint for succinate dehydrogenase mutation D.⁷ Succinate dehydrogenase mutation A has not yet been associated with paraganglioma, and the gene for paraganglioma two syndrome is still unidentified.^{8,9}

The three paraganglioma syndromes have different clinical presentations;⁹ paraganglioma one and four are associated with pheochromocytoma, paraganglioma one with multiple tumours, and paraganglioma four with malignant tumours.⁸ Recently, Benn *et al.* reported data on genotype and phenotype associations in a cohort of 116 patients with pheochromocytoma–paraganglioma syndromes and succinate dehydrogenase mutations B and D. Succinate dehydrogenase mutation B carriers were more likely than mutation D carriers to develop extra-adrenal pheochromocytomas and malignant disease, whereas mutation D carriers had a greater propensity to develop head and neck paragangliomas and multiple tumours.¹⁰ Paraganglioma three (succinate dehydrogenase mutation C) has been linked to carotid body tumours in young patients.⁹ The mutation identified in our patient, c.183G>A (p.Trp61X), is clearly a disease-causing mutation. Not all the succinate dehydrogenase C-type mutations are deleterious; indeed, missense mutations exist, the significance of which is not clear.¹¹




FIG. 3

Microscopic view of the paraganglioma. (a) H&E staining showing uniform round or polygonal chief cells forming compact cell nests ('zellballen') surrounded by a delicate capillary network ($\times 400$). (b) Immunohistochemical staining for chromogranin A, with positive cell reactivity ($\times 400$). (c) Staining for S-100 protein, demonstrating the sustentacular cells, an important feature in the differentiation from other endocrine neoplasms ($\times 400$).

- **Paragangliomas are uncommon neuroendocrine tumours arising from neural crest tissue found in various locations around the body**
- **Hereditary paragangliomas are caused by germline mutation in the genes coding for mitochondrial complex II**
- **This paper describes a rare case of a laryngeal paraganglioma related to succinate dehydrogenase gene mutation C**
- **Every patient with paraganglioma should be tested for succinate dehydrogenase genetic mutations, even if a family history of paraganglioma is absent, in order to allow appropriate clinical management and to improve our knowledge of familial paraganglioma**

Papillary thyroid cancer has been reported previously in one case of paraganglioma one and in one case of paraganglioma four,⁸ without inferring a similar genetic origin for the thyroid cancer. In the same way, we report such an association that has probably been caused purely by

chance, since papillary thyroid carcinoma is a highly prevalent malignancy. However, the succinate dehydrogenase mutation C identified in our patient is extremely rare, with only 22 reported cases in the English language literature.⁹ Such an association with malignancy should be reported, in order to improve our knowledge of familial paraganglioma.

The case presented here underlines the fact that the genetic investigation of paraganglioma is still in its early stages, and that every patient with paraganglioma should therefore be tested for succinate dehydrogenase genetic mutations, even if a family history of paraganglioma is absent, to allow appropriate clinical management and to improve our knowledge of familial paraganglioma.

Acknowledgements

The authors wish to thank Dr Sophie Giraud from the Unité de Génétique Moléculaire, Hôpital Edouard Herriot, Lyon, France, for the genetic analysis.

References

- 1 Terracol J, Guerrier Y. Tumoral syndrome of glomus jugulaire [in French]. *Presse Med* 1952;**60**:715–16

- 2 Guerrier B, Makeieff M, Louche C, Mouketou JB, Crampette L. Cervical paraganglioma. Results for a series of 33 patients [in French]. *Ann Otolaryngol Chir Cervicofac* 1994;**111**:427–34
- 3 Ferlito A, Devaney KO, Rinaldo A. Neuroendocrine neoplasms of the larynx: advances in identification, understanding, and management. *Oral Oncol* 2006;**42**:770–88
- 4 Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A *et al.* Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. *Science* 2000;**287**:848–51
- 5 Rieu M, Lame MC, Richard A, Lissak B, Sambort B, Vuong-Ngoc P *et al.* Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. *Clin Endocrinol (Oxf)* 1995;**42**:453–60
- 6 Fuller RH. Tumor of the glomus jugularis; report of a case. *U S Nav Med Bull* 1949;**49**:1141–4
- 7 Hensen EF, Jordanova ES, van Minderhout IJ, Hogendoorn PC, Taschner PE, van der Mey AG *et al.* Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and pheochromocytoma families. *Oncogene* 2004;**23**:4076–83
- 8 Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M *et al.* Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. *JAMA* 2004;**292**:943–51
- 9 Schiavi F, Boedeker CC, Bausch B, Peczkowska M, Gomez CF, Strassburg T *et al.* Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. *JAMA* 2005;**294**:2057–63
- 10 Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K *et al.* Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. *J Clin Endocrinol Metab* 2006;**91**:827–36
- 11 Bayley JP, van Minderhout I, Weiss MM, Jansen JC, Oomen PH, Menko FH *et al.* Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma. *BMC Med Genet* 2006;**7**:1

Address for correspondence:
 Dr Renaud Garrel MD, PhD
 ENT Head & Neck surgery department
 Pole of Neuro Sciences, Head & Neck
 Gui de Chaulial Hospital
 Montpellier's Teaching Hospitals
 80 rue Fliche, 34295 Montpellier Cedex 4 (France).

Fax: +33 (0) 4 67 33 67 28
 Tel: 33 (0) 4 67 33 68 03
 E-mail: r-garrel@chu-montpellier.fr

Dr R Garrel takes responsibility for the integrity of the content of the paper.
 Competing interests: None declared
